Clinical trial NCT00252941 - References

Prostate Cancer — Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma

Citation(s)

•   Benoit RM, Naslund MJ, Cohen JK
  A comparison of complications between ultrasound-guided prostate brachytherapy and open prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):909-13.
•   Blasko JC, Ragde H, Grimm PD
  Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl. 1991;137:113-8.
•   Bruno JF, Whittaker J, Song JF, Berelowitz M
  Molecular cloning and sequencing of a cDNA encoding a human alpha 1A adrenergic receptor. Biochem Biophys Res Commun. 1991 Sep 30;179(3):1485-90.
•   Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AF, Abrams P
  Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):155-67.
•   Elshaikh MA, Ulchaker JC, Reddy CA, Angermeier KW, Klein EA, Chehade N, Altman A, Ciezki JP
  Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study. Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):164-9.
•   Henderson A, Laing RW, Langley SE
  A Spanner in the works: the use of a new temporary urethral stent to relieve bladder outflow obstruction after prostate brachytherapy. Brachytherapy. 2002;1(4):211-8.
•   Kleinberg L, Wallner K, Roy J, Zelefsky M, Arterbery VE, Fuks Z, Harrison L
  Treatment-related symptoms during the first year following transperineal 125I prostate implantation. Int J Radiat Oncol Biol Phys. 1994 Mar 1;28(4):985-90.
•   Konety BR, Phelan MW, O'Donnell WF, Antiles L, Chancellor MB
  Urolume stent placement for the treatment of postbrachytherapy bladder outlet obstruction. Urology. 2000 May;55(5):721-4.
•   Lee N, Wuu CS, Brody R, Laguna JL, Katz AE, Bagiella E, Ennis RD
  Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1457-60.
•   Lepor H
  Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology. 1998 Jun;51(6):901-6.
•   Lepor H
  Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998 Jun;51(6):892-900.
•   Nag S, Beyer D, Friedland J, Grimm P, Nath R
  American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):789-99. Review.
•   Nag S, Bice W, DeWyngaert K, Prestidge B, Stock R, Yu Y
  The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):221-30. Review.
•   Perry MJ, Roodhouse AJ, Gidlow AB, Spicer TG, Ellis BW
  Thermo-expandable intraprostatic stents in bladder outlet obstruction: an 8-year study. BJU Int. 2002 Aug;90(3):216-23.
•   Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester JE, Hoak DC, Landin K, Cavanagh W
  Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer. 1997 Aug 1;80(3):442-53.
•   Ragde H, Korb LJ, Elgamal AA, Grado GL, Nadir BS
  Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer. 2000 Jul 1;89(1):135-41.
•   Ramarao CS, Denker JM, Perez DM, Gaivin RJ, Riek RP, Graham RM
  Genomic organization and expression of the human alpha 1B-adrenergic receptor. J Biol Chem. 1992 Oct 25;267(30):21936-45.
•   Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ
  Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):145-54.
•   Terk MD, Stock RG, Stone NN
  Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol. 1998 Oct;160(4):1379-82. Review.

The Role Of Prophylactic Urethral Stenting With Memokath® 028SW in Patients Undergoing Prostate 125I Seed Implants For Prostate Carcinoma: A Phase I/II Study

Details for clinical trial NCT00252941